Hyperion Therapeutics Inc., of South San Francisco, said population pharmacokinetic (PK) modeling and dosing simulations from Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate) were reported in The Journal of Clinical Pharmacology based on data from four Phase II and III trials that enrolled patients with urea cycle disorders (UCDs...Mei Pharma Inc., of San Diego, said the first patients were dosed in a Phase II trial of its lead candidate, HDAC inhibitor Pracinostat, in

Astex Pharmaceuticals Inc., of Dublin, Calif., presented updated clinical results of its hypomethylating agent, SGI-110, in a poster session at the 18th Congress of the European Hematology Association in Stockholm, Sweden...The update focused on details of the biological and clinical activity as well as safety in the group of intermediate or high-risk relapsed or refractory myelodysplastic syndromes patients treated in the dose-escalation, Phase I part of the SGI-110-01 study...Of the 15 patients, six

Meanwhile, Gary Burgess, senior vice president of clinical research and chief medical officer, joined Conatus in 2011 from Pfizer, where he oversaw the assimilation of Idun, including data integration, clinical oversight of ongoing Phase II studies, development of clinical plans and registration strategies for emricasan...In all, emricasan has completed nine clinical studies, including some at Pfizer, enrolling more than 500 participants, according to Conatus

The study demonstrated the superiority of ozenoxacin 1 percent cream, applied topically for five days, compared to placebo on both clinical and bacteriological endpoints by end-of-therapy visit (day six to seven

TAIPEI, Taiwan – Diminutive drug discovery firm PRISM Pharma Co...of Japan (INCJ), together with existing PRISM Pharma investor DBJ Capital, a VC fund started by the government-owned Development Bank of Japan...And although full terms of the Series C funding round were not disclosed, they did include the hitting of milestones on the fibrosis clinical trial, according to PRISM Pharma CFO, Dai Takehara

With data from the first clinical trial of anti-TNF polyclonal antibody AVX-470 in ulcerative colitis (UC) due toward the end of this year, Avaxia Biologics Inc...The big pharma will be able to exercise its option upon the conclusion of Phase IIb testing of ALV003, a two-enzyme combination candidate designed to degrade gluten. (See BioWorld Today, May 15, 2013.) According to Avaxia, IBD refers to related but different diseases: ulcerative colitis (UC), which affects the colon, and Crohn's disease

and its partner Astellas Pharma Inc...The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011

Data from an ongoing Phase I/II study confirmed clinical evidence of the antitumor activity at multiple dose levels in patients with anaplastic lymphoma kinase-positive NSCLC, including brain metastases, and initial clinical evidence of antitumor activity in patients with EGFR receptor mutation NSCLC. (See BioWorld Today, Dec. 17, 2012...and the clinical benefit response rate was 82 percent

The first-in-man trial will be undertaken by the National Institute of Health Research Experimental Cancer Medicine Centre, based at the Northern Institute of Cancer Research at Newcastle University, as well as at least one other clinical center

Those results were presented at the New Clinical Drug Evaluation Unit meeting in Hollywood, Fla...Omeros Corp., of Seattle, said it filed a clinical trial application with European regulators to initiate clinical trials of OMS721, its lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2, or MASP-2, program...Zealand Pharma A/S, of Copenhagen, Denmark, and partner Helsinn Group, of Lugano, Switzerland, reported that Helsinn concluded a Phase IIa study with

Results of the PROLASTIN-C SPARK study, a multidose pharmacokinetic clinical trial, were presented at the annual meeting of the American Thoracic Society in Philadelphia

GW Pharma plc (NASDAQ:GWPH) commenced trading on May 1, pricing at $8.90, and closed at $8.88 Wednesday...And Lyon, France-based Erytech Pharma SA commenced trading in Paris at €11.60 per share, raising €16.7 million (US$21.4 million) for the company...The company's platform technology is designed to improve drug delivery into internal body cavities.

SONAR is a multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy...Destiny Pharma Ltd., of Brighton, UK, reported progress in the Phase I U.S...The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is being conducted at the NIAID Phase I Clinical Trials Unit at Case Western Reserve University in Cleveland

Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Kite Pharma Inc., of Los Angeles, said it closed a $20 million private placement of shares of its Series A preferred stock...Receptos will use the proceeds to support clinical work in multiple sclerosis, inflammatory bowel disease and allergic/immune-mediate disorders. (See BioWorld Today

BioAlliance Pharma SA, of Paris, reported the International Independent Board of Experts' data and safety monitoring board (DSMB) again recommended continuing the ReLive Phase III trial without modification...Mirna Therapeutics Inc., of Austin, Texas, has initiated a Phase I study of MRX34, the first miRNA to advance to a clinical trial for cancer

Eisai Inc., of Woodcliff Lake, N.J., said antiepileptic drug Fycompa (perampanel) showed a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy, according to two new analyses of early clinical experience

clinical development plan and financial terms relating to ISIS-TTRRx to reflect an accelerated development plan for that antisense drug...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months

The study, dubbed Gammaglobulin Alzheimer's Partnership, was conducted in collaboration with the Alzheimer's Disease Cooperative Study, a clinical trial consortium supported by the National Institute on Aging

Astellas Pharma Inc., of Tokyo, and Drais Pharmaceuticals Inc., of Bridgewater, N.J., will repeat for the third time a spinout maneuver that has been successful with two other programs in the past...In April 2012, Astellas transferred ownership of ASP3291, a melanocortin receptor agonist for ulcerative colitis, to Telsar Pharma Inc., with a $14 million investment by InterWest and Sutter Hill, to begin Phase IIa testing. (See BioWorld Today, Nov. 1, 2013.) And in June 2012, Drais partnered with